Background/Aims: Solamargine, one natural photochemical component from traditional plants, has been shown to have anti-cancers properties. We previously showed that solamargine inhibited the growth of non-small-cell lung cancer (NSCLC) cells through suppression of prostaglandin E2 (PGE 2 ) receptor EP4 gene and regulation of downstream signaling pathways. However, the detailed mechanism underlying this, especially in combination of metformin, a known AMPK activator, still remained to be determined. Methods: Cell viability was measured using a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) and colorimetric 5-bromo-2-deoxyuridine (BrdU) ELISA methods, respectively. Western blot analysis and immunohistochemistry were performed to examine the phosphorylation and protein expressions of signal transducer and activator of transcription 3 (Stat3), SP1, forkhead box O3a (FOXO3a), and insulin-like growth factor (IGF)-IGF binding protein 1 (IGFBP1). The expression of IGFBP1 mRNA was measured by quantitative real time PCR (qRT-PCR). Silencing of FOXO3a and IGFBP1 were examined by siRNA procedures. Exogenously expression of SP1, FOXO3a, and IGFBP1 were carried out by transient transfection assays. The promoter activity of IGFBP1 was tested using Secrete-Pair™ Dual Luminescence Assay Kit. A xenografted tumor model was used to further test the effect of solamargine in combining with metformin in vivo. Results: We further demonstrated that solamargine inhibited growth and induced cell cycle arrest in other NSCLC cell lines. Through mechanism-based approaches, we showed that solamargine decreased the phosphorylation of Stat3; In addition, solamargine induced FOXO3a, whereas reduced SP1 protein levels; all of which were abrogated in cells with overexpressed Stat3 gene. Interestingly, there is interaction between FOXO3a and SP1. Moreover, solamargine increased mRNA, protein expression and promoter activity of IGFBP1, which was not observed in cells with overexpressed SP1 or with silenced FOXO3a genes. Finally, ablation of IGFBP1 expression by siRNA blocked the effect of solamargine on cell growth inhibition. More importantly, there was a synergy of combination of solamargine and metformin. Similar findings were also observed in vivo. Conclusion: Our results show that solamargine increases IGFBP1 gene expression through inactivation of Stat3, followed by regulation and reciprocal interaction of FOXO3a and SP1 in vitro and in vivo. This ultimately leads to suppression of human lung cancer cell growth. Moreover, this is a synergy of solamargine in combination with metformin in this process. This study unravels a novel mechanism underlying the anti-lung cancer effects of solamargine in combination of metformin, and suggests a potential new lung cancer associated therapy.
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Introduction
Lung cancer is one of life threatening malignancies with the highest incidence and mortality among cancer types worldwide. Non-small cell lung cancer (NSCLC) accounts for 80% to 85% of lung cancer cases, mostly diagnosed at advanced stages [1] . Although substantial efforts have been made using comprehensive treatment modalities, the 5-year survival rate still remains poor because of uncontrolled local or recurrent disease due to limited treatment efficacy and information available in understanding of the mechanisms of this illness [1, 2] . Thus, the continuing efforts have been made in selecting other therapeutic options for the intervention of this malignancy to improve the quality of life and prolong the survival.
Signal transducer and activator of transcription 3 (Stat3), a member of the Stat family of transcription factors, is highly activated and expressed in several cancer types, and involved in several biological functions such as inflammation, proliferation, progression and metastasis in cancer [3] [4] . Blockade of Stat3 has been shown to inhibit cell proliferation, induced apoptosis, and suppressed tumor formation [5, 6] . Thus, targeting this signaling pathway could be a potential therapeutic approach for the prevention and treatment of cancer [3, 6, 7] .
Transcription factors of the forkhead box, class O (FOXO) family are crucial regulator of the cellular responses and play an important role in inhibition of tumor growth by influencing several downstream targets involved in cell cycle arrest, apoptosis, and proliferation [8] . Among the four members (FOXO1, FOXO3a, FOXO4 and FOXO6), FOXO3a is the more extensively studied. Numerous studies have demonstrated that FOXO3a regulated a wide range of biological functions including growth, differentiation, apoptosis, protection against oxidative stress, and metabolism [9] [10] [11] . Exogenously expression of FOXO3a has been shown to inhibit tumor growth in several cancer types [12, 13] . These observations suggest that FOXO3a functions as a tumor suppressor and may serve as a therapeutic target for the cancer treatment. However, studies have also observed that FOXO3a promotes cancer cell growth under oxidative stress [14] and serum deprivation condition [15] . Therefore, the true role of FOXO3a in cancer biology could be more complicated than we thought and warranted to be determined.
A number of studies have shown that natural compounds have anticancer properties. Solamargine, a plant derived steroidal glycoalkaloid, has been found to inhibit growth and induce apoptosis in several cancer types [16] [17] [18] [19] [20] . Solamargine reduced the growth of metastatic and primary melanoma cells via disrupting the intrinsic apoptosis pathway [20] . We previously found that solamargine reduced the proliferation of NSCLC cells through inhibition of prostaglandin E2 (PGE 2 ) receptor EP4, DNA methyltransferase 1 (DNMT1), and c-Jun expressions [21, 22] . However, the detailed mechanisms and potential benefits underlying the effects of solamargine in prevention and treatment of NSCLC still remain to be determined.
The insulin-like growth factor (IGF)-IGF binding proteins (IGFBPs) play important roles in physiology and pathophysiology, such as development, metabolism, insulin sensitivity, mitochondrial protection, cell growth, differentiation and apoptosis [23] [24] [25] . Among six high-affinity binding proteins (IGFBP1 to 6), IGFBP1，which is abundantly expressed in the liver and decidualized endometrium [26] , interacts with not only its canonical ligands IGF-I and IGF-II, but also other proteins, and involves in tumorigenesis, growth, invasion and metastasis of cancer [27, 28] . Report showed that excess of IGFBP1 inhibited growth of breast cancer cells via inhibition of IGF receptor 1 binding to IGFs [29] . High expression of IGFBP mRNA was strongly correlated with better survival in breast cancer mouse model [30] . We previously observed that ursolic acid, a natural pentacyclic triterpenoid, and emodin, one anthraquinones constituents derivative isolated from the roots of rheum palmatuma, inhibited growth of hepatocellular carcinoma and lung cancer cells through induction of IGFBP1 gene expression, suggesting tumor suppressing role of this molecule [31, 32] . However, conflicting results were observed in other cancer types, such as prostate [33, 34] and endometrial cancer [35] and others [36] . Thus, IGFBP1 may play dual roles depending upon the environmental content, cells examined, and agents exposed. More importantly, information and data available for the expression and function of IGFBP1 in lung cancer are limited, and the detailed mechanism underlying the anti-lung cancer effect of solamargine still remains to be elucidated.
In this study, we further explored the potential mechanism by which solamargine inhibited growth of NSCLC cells. We provided additional evidence showing that combination of solamargine and metformin, a drug for the treatment of type 2 diabetes, strengthened IGFBP1 gene expression through inactivation of Stat3, followed by regulation of FOXO3a and SP1 expressions in vitro and in vivo.
Materials and Methods
Reagents and cell cultures
Antibodies against the total Stat3 and phosphor-Stat3 (Tyr705), and FOXO3a were purchased from Cell Signaling Technology Inc. (Beverly, MA, USA). The SP1, IGFBP1 and GAPDH antibodies were obtained from Abcam (Cambridge, MA, USA). MTT powder was purchased from Sigma Aldrich (St. Louis, MO, USA). FOXO3a and IGFBP1 small interfering RNAs (siRNAs) and Lipofectamine 3000 reagent were obtained from AB & Invitrogen (Carlsbad, CA, USA). Solamargine was obtained from Chengdu Must Bio-technology Company (Chengdu, Sichuan, China), which was dissolved in water and diluted to the final concentration with culture medium before use. Other chemicals were purchased from Sigma Aldrich unless indicated (St. Louis, MO, USA). Human lung cancer cells (A549, PC9, H1299, H1650, H358, H1359 and H1975) were obtained from the Cell Line Bank at the Laboratory Animal Center of Sun Yat-sen University (Guangzhou, China) and the Chinese Academy of Sciences Cell Bank of Type Culture Collection (Shanghai, China), and have been authenticated for absence of Mycoplasma, genotypes, and morphology using a commercial available kit by Guangzhou Cellcook Biotech Co., Ltd (Guangzhou, China). Cells were cultured at 37° C in a humidified atmosphere containing 5% CO2. The culture medium consisted of RPMI 1640 medium from Life Technologies (Carlsbad, CA, USA) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (Invitrogen, Grand Island, NY), 100 µg/ml streptomycin and 100 U/mL penicillin (Sigma-Aldrich, St. Louis, MO). In addition, the medium of A549-luc cells was added Geneticin (G-418）Sulfate (200 μg/mL, Life Technologies, Carlsbad, CA, USA).
Cell viability assay
Cell viability was examined using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay as reported previously [37] . NSCLC cells (5×10 3 cells/well) seeded into 96-well microtiterplate were treated with increasing concentrations of solamargine for up to 72 h. Afterwards, 10 mL of MTT (5 mg/ ml) was added to each well and incubated for an additional 3 h. After removing supernatant, the formazan product was dissolved by adding 150 µL solvent dimethyl sulfoxide (DMSO) and optimal density was determined with 490 nm by ELISA reader (Perkin Elmer, Victor X5, Waltham, MA, USA). 
Quantitative real-time PCR
A quantitative real-time PCR (qRT-PCR) assay was performed to examine IGFBP1 transcripts. The primers used in this study were designed as follows: IGFBP1 forward 5'-TCACAGCAGACAGTGTGAGAC -3'; reverse 5'-CCCAGGGATCCTCTTCCCAT -3'; GAPDH forward 5'-AAGCCTGCCGGTGACTAAC-3'; reverse 5'-GCGCCCAATACGACCAAATC -3'. Total RNA (2 μg) was reverse-transcribed using oligo-dT primers and Superscript II reverse transcriptase (Invitrogen, Grand Island, NY, USA) according to the manufacturer's instructions. Quantitative real-time PCR was performed in a 20 μL mixture containing 2 μL of the cDNA preparation, 10 μL 2X SYBR Green Premix ExTaq (Takara, Japan), and 10 μM primer on an ABI 7500 RealTime PCR System (Applied Biosystems, Grand Island, NY, USA). The PCR conditions were as follows: 30s at 95 °C, followed by 40 cycles of 5s at 95 °C and 34s at 60°C. Finally, 15s at 95°C，60s at 60°C and 15s at 95 °C. Threshold values were determined for each sample/primer pair, the average and standard errors were calculated. Relative expression of IGFBP1 was calculated as ΔC t , measured by subtracting the C t of the GAPDH.
Western blot analysis
Western blot analysis was performed as described previously [37] . Equal amount of protein from whole cell lysates were solubilized in 2x SDS-sample buffer and separated by 10% SDS polyacrylamide gels, and electroblotted onto membranes (Millipore, MA, USA). Membranes were incubated with antibodies against phosphor-Stat3, total Stat3, FOXO3a, IGFBP1 and SP1 (1:1000). The membranes were later incubated with a secondary antibody conjugated to horseradish peroxidase (1:3000, Cell Signaling, Beverly, MA, USA). The membranes were washed again and transferred to freshly made ECL solution, and visualized using the enhanced chemiluminescence detection system (Immobilon Western; Millipore, Billerica, MA, USA). The signals were captured using the Gel Imagine System (Bio-Rad, Hercules, CA, USA).
Treatment with FOXO3a and IGFBP1 siRNAs
The detailed procedure was reported previously [37] . For the transfection procedure, cells were seeded in 6-well or 96-well culture plates in RPMI 1640 medium containing 10% FBS (no antibodies), grown to 60% confluence, and FOXO3a, IGFBP1 and control siRNAs purchased from Life Technologies (Carlsbad, CA, USA), were transfected using Lipofectamine 3000 according to the manufacturer's instructions (Invitrogen, Waltham, MA, USA). After culturing for up to 30 h, the cells were resuspended in fresh media in the presence or absence of solamargine for an additional 24 h for all other experiments.
Transient transfection assays
The detailed procedure was reported previously [38] . NSCLC cells were seeded at a density of 2 x10 5 cells/well in 6-well dishes and grown to 50 -60% confluence. For each well, control and wild type pEZX-PG04-IGFBP1 promoter constructs (purchased from GeneCopoeia, Inc., Rockville, MD, USA) with or without 0.2 µg of secreted alkaline phosphatase (SEAP) were co-transfected into the cells with the Lipofectamine 3000 Transfection Reagent. The preparation of cell extracts and measurement of luciferase activities were determined using the Secrete-Pair™ Dual Luminescence Assay Kit (GeneCopoeia, Inc., Rockville, MD, USA). Luciferase activity (actual luminescence units) was normalized with SEAP within each sample. In the separate experiments, the desired N1-GFP or FOXO3a-GFP plasmid DNA, kindly provided by Frank M. J. Jacobs (Rudolf Magnus Institute of Neuroscience, Department of Pharmacology and Anatomy, University Medical Center, Utrecht, Netherlands) and was reported previously [39] , the control (pcDNA3.1), SP1 overexpression pcDNA3.1Sp1/flu vector (kindly provided by Dr. Thomas E. Eling, National Institute of Environmental Health Sciences, USA) [40] , the control (pCMV-6) and IGFBP1 expression vectors (IGFBP1-pCMV6-AC-GFP) purchased from OriGene Technologies, Inc. (Rockville, MD, USA), at a final concentration of 2 mg/mL were transfected into the cells with the Lipofectamine 3000 reagent. Cells were incubated for 24 h at 37°C, then treated with solamargine for the indicated time for all other experiments. Co., Guangzhou, China) (2x10 6 cells), which were cultured in medium with Geneticin (G-418, Sulfate, Life Technologies, USA) at concentration of 200 μg/mL, were injected subcutaneously in the upper hind limb of mice. Xenografts were expected to grow for 8 th days when the initial measurement was available. Mice were randomly divided into control, metformin (250 mg/kg, obtained from Enzo Biochem, NY, USA), solamargine (6 mg/kg), and metformin (250 mg/kg) plus solamargine (6 mg/kg groups), which given once a day via gavages and intraperitoneal injection for up to 27 days (n=9/group), which were based on other and our previous studies [22, 41, 42] .
In vivo experiments
Next, mice were anesthetized by inhalation of 2% isoflurane. The substrate D-luciferin (Caliper Life Sciences, Hopkinton, MA, USA) was injected into the peritoneal cavity with a dose of 150 mg/kg in approximately 100 mL. The intensity of bioluminescence imaging (BLI) signal was determined using the IVIS-200 Imaging System (Xenogen/Caliper, Alameda, CA, USA). The formula for an oblong sphere: volume = (width 2 × length) were used for measuring tumor volume. Quantification of bioluminescence was reported as photons/sec. The body weights of the mice were measured once a week. All mice were sacrificed on day 27 in accordance with the Guide for the Care and Use of Laboratory Animals. At the end of the experiments, xenografted tumors were isolated from individual animals and the corresponding lysates were processed and detected FOXO3a, SP1 and IGFBP1 by Western blot with the indicated antibodies.
Immunohistochemistry (IHC)
Immunohistochemical assay was used to determine SP1, FOXO3a and IGFBP1 protein expressions in xerografted tumors, which were fixed in 10% formaldehyde for 24 h and then embedded with paraffin. The specimens were cut into 5 μm sections and antigenic retrieval was performed in citric acid buffer (pH 6.0). Sections were incubated with primary antibody against IGFBP1 (dilutions of 1:50，Abcam, UK)，SP1, FOXO3a (dilutions of 1:100, Cell Signaling Technology, USA）at 4 ℃ overnight, followed by incubating with second antibody (Maixin Biotech. Co. Ltd, Fuzhou, China) for 30 mins. Detection was performed using 3, 3′-diaminobenzidine (DAB) chromogen kit (Maixin Biotech. Co. Ltd, Fuzhou, China). Pictures were taken under 200× magnification by BX53+DP72 Microscope (Olympus Corporation，Tokyo, Japan). The immunostaining was evaluated by Image-Pro Plus 6.0 image analysis software (Media Cybernetics, Inc. Sliver Spring, MD, USA) in at least five random high-power fields.
Statistical analysis
Statistical analysis was carried out using GraphPad Prism version 5.04 for Windows (GraphPad Software, La Jolla, CA, USA). All data are expressed as mean±SD. Differences between groups were assessed by one-way ANOVA and significance of difference between particular treatment groups was analyzed using Dunnett's multiple comparison tests. Asterisks showed in the figures indicate significant differences of experimental groups in comparison with the corresponding control one. In all analyses, P-values < 0.05 were considered as statistically significant
Results
Solamargine inhibited cell growth and induced cell arrest in lung cancer cells
We previous showed that solamargine inhibited growth of human lung cancer A549 cells [21] . In the current study, we further assessed the relative contribution of inhibition affected by solamargine. As expected, we observed that, compared with the untreated control cells, solamargine significant inhibited growth of NSCLC PC9 cells using MTT assays (Fig. 1A) and in both A549 and PC9 cells using colorimetric BrdU ELISA methods (Fig. 1B) . The similar results were also observed in other NSCLC cell lines as determined by MTT assays (Fig. 1C) . The results above further indicated the anti-lung cancer effects of solamargine. Moreover, we found that combination of solamargine and metformin, a known AMPK activator and drug for the treatment of type 2 diabetes which has been shown to have anti-tumor effects [43] , enhanced the effect of cell growth inhibition (Fig. 1D) arrest at G0/G1 phases ( Fig. 1E ) as compared to that in the solamargine alone. This implied potential synergy in this process.
Solamargine increased phosphorylation of Stat3 in lung cancer cells
To gain insight into the potential signaling pathways involving in solamargine-inhibited growth of lung cancer cells, we then set up to examine the effect of solamargine on Stat3 signaling. Stat3 is recognized as a transcription factor that modulates the transcription of a variety of genes that have been involved in important biological functions including cell proliferation, differentiation, survival, angiogenesis, immune response and cancer biology [9] [10] [11] . We found that solamargine (6 μM) decreased phosphorylation of Stat3, while it had no effect on total Stat3 protein expression in A549 and PC9 cells (Fig. 2A) . Interestingly, the combination of solamargine and metformin enhanced the effect of inactivation of Stat3 in A549 and PC9 cells (Fig. 2B) .
Solamargine elevated FOXO3 protein and reduced SP1 protein expression through inactivation of Stat3
We also searched for the potential downstream effectors of Stat3 that regulated by solamargine. We first assessed the effect of solamargine on transcription factors FOXO3a and 
concentrations of SM for 48 h, followed by processing for measuring cell growth as determined by colorimetric BrdU ELI-SA methods described in the Materials and Methods section. C, NSCLC cell lines indicated were treated with SM (6 μM) for 48 h, followed by measuring cell viability by MTT assay. D, A549 and PC9 cells were treated with SM (6 μM) and metformin (5 mM) for up to 48 h, followed by measuring the cell viability by MTT assays. E, A549 cells were treated with SM (6 µM) in the presence or absence of metformin (5 mM) for up to 48 h. Afterwards, the cells were collected and processed for analysis of cell cycle distribution by flow cytometry. The percentages of the cell population in each phase (G0/G1, S and G2/M) were assessed by Multicycle AV DNA Analysis Software. Values are given as the mean ± SD, from 3 independent experiments performed in triplicate. *indicates a significant difference from the control group (P<0.05). **Indicates significance of combination treatment as compared to SM alone (P<0.05).
Cellular
SP1 that linked to the Stat3 signaling and regulated a number of cellular functions involving in tumorigenesis, tumor progression, apoptosis, and metastasis [44, 45] . We showed that solamargine elevated FOXO3a protein levels in A549 and PC9 cells (Fig. 3A) . On the contrary, solamargine decreased SP1 protein expression (Fig. 3B) . As expected, the combination of solamargine and metformin enhanced the effect of reduction of SP1 and induction of FOXO3a proteins ( Fig. 3C-D) . Intriguingly, we also showed that exogenously expressed Stat3 overcame the effect of solamargine on FOXO3a and SP1 protein expressions (Fig. 3E) . Interestingly, we observed that, while exogenously expressed FOXO3a had little effect on solamarginedecreased SP1 protein, overexpressed SP1 significantly resisted the effect of solamargine on FOXO3a protein expression, suggesting SP1 may be upstream of FOXO3a in this process ( Fig. 3F-G) . Together, the results above implied that inactivation of Stat3 was required in mediating the effects of solamargine -reduced SP1 and -induced FOXO3a proteins.
Solamargine induced expression of IGFBP1 protein, mRNA, and promoter activity
To further explore the potential downstream targets that mediated the anti-lung cancer effect of solamargine, we investigated the role of IGFBP1, which was secreted from the liver and had a protective role in the development of cancer [23, 24, 46] . We showed that solamargine increased not only protein and mRNA levels of IGFBP1 as determined by Western Blot and qRT-PCR (Fig. 4A-B) , but also IGFBP1 promoter activity as determined by SecretePair™ Dual Luminescence Assay Kit (Fig. 4C) . Of note, the combination of solamargine and metformin enhanced IGFBP1 protein expression (Fig. 4D) .
Interaction between FOXO3a and SP1 contributed to the induction of IGFBP1 expression by solamargine
To explore the functional relevance of transcriptional factors that involved in the upregulation of IGFBP1 expression, we further investigated the role of FOXO3a and SP1. A, A549 and PC9 cells were exposed to increased concentrations of SM for 24 h, followed by measuring the phosphorylation and protein expression of Stat3 by Western blot. The bar graphs represented the mean ± SD of p-Stat3, Stat3/ GAPDH of three independent experiments. B, A549 and PC9 cells were treated with SM (6 μM) and metformin (5 mM) for up to 24 h. afterwards, the phosphorylation of Stat3 was measured by Western blot. The bars represented the mean ± SD of p-Stat3/GAPDH at least three independent experiments for each condition. *Indicates significant difference as compared to the untreated control group (P<0.05); **Indicates significance of combination treatment as compared to SM alone (P<0.05).
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Tang et al.: Combination of Solamargine and Metformin Strengthens IGFBP1 Gene Expression
Report showed that IGFBP1 promoter contained FOXOs and SP1 binding sites and that FOXOs and SP1 could regulate IGFBP1 gene expression and its downstream signaling [47] [48] [49] . Importantly, we found that either silencing of FOXO3a or exogenously expressed SP1 overcame the effect of solamargine on IGFBP1 expression in both A549 and PC9 cells (Fig.  5A-B) . Conversely, overexpression of FOXO3a enhanced the effect of solamargine on IGFBP1 expression (Fig. 5C) . Together, the above results indicated that FOXO3a and SP1, acting as upstream signals of IGFBP1, interacted with each other to regulate the expression of IGFBP1 in NSCLC cells. We further characterized the ability of IGFBP1 to regulate cell growth and regulation of Stat3. While overexpression of IGFBP1 had no effect on feedback regulation of Stat3 activation (Fig. 5D) ; it resisted the effect of solamargine on cell growth inhibition (Fig.  5E ) implying a critical role of IGFBP1 induction in this process.
In vivo anti-tumor efficacy of solamargine in nude mice model
In order to prove the results in vitro, we tested the effect of solamargine on lung cancer xenografts in nude mice model. Luciferase-expressing A549 cells (A549-Luc) were injected subcutaneously in nude mice followed by intraperitoneal injection of D-luciferin. Mice bearing xenografted tumors were treated with control, metformin, solamargine alone, and combination of metformin and solamargine via garages (metformin) or/and intraperitoneal injection (solamargine) for up to 27 days. We observed that, compared to the control group, the metfromin-or solamargine-treated mice demonstrated a significant growthinhibitory effect as assessed by the Xenogen IVIS200 System (Fig. 6A) . More importantly, a further inhibitory outcome was observed in the combination treatment group (Fig. 6A) . In addition, we found a substantial reduction of the tumor weight and size in the metformin-, or solamargine-treated groups as compared to that in the control group (Fig. 6B-D) . As expected, a further inhibitory effect was noticed in the combination group (Fig. 6B-D) . Moreover, consistent with the results from that in the in vitro data, the reduced expression of SP1, whereas increase in FOXO3a and IGFBP1 proteins from fresh tumors harvested from the above experiment were observed in the metformin-, or solamargine-treated groups as compared to that in the control group (Fig. 6E) . Note that the combination treatment showed even greater effects (Fig. 6E) . As expected, the immunohistochemistry results also unveiled the similar results (Fig. 6F) . and PC9 cells were exposed to increased concentrations of SM for 24 h, followed by measuring the protein and mRNA expressions of IGFBP1 by Western blot and qRT-PCR, respectively. C, A549 and PC9 cells were transfected with a wild type human IGFBP1 promoter reporter construct ligated to luciferase reporter gene and an internal control secreted alkaline phosphatase for 24 h, followed by treating with SM for an additional 24 h. Afterwards, the promoter activities were determined using the Secrete-Pair Dual Luminescence Assay Kit as described in the Materials and Methods section. D, Cellular protein was isolated from A549 and PC9 cells treated with SM (6 µM) in the presence or absence of metformin (5 mM) for up to 24 h. Afterwards, the expression of IGFBP1 protein was detected by Western blot. The bar graphs represented the mean ± SD of IGFBP1/GAPDH of three independent experiments. *Indicates significant difference as compared to the untreated control group (P<0.05); **Indicates significance of combination treatment as compared to SM alone (P<0.05).
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Discussion
In this study, we presented several lines of evidence from protein expression regulation, proliferation, and xenograft experiments in vivo to demonstrate the critical role of IGFBP1 as a tumor suppressor in mediating the anti-cancer effects of solamargine and metformin. Our results indicated that inactivation of Stat3, followed by interaction and regulation of transcription factors FOXO3a and SP1 contributed to the induction of IGFBP1 expression by solamargine in vitro and in vivo.
Growing interest has focused on the use of natural plants to reduce the incidence and mortality of cancer, leading to encouraging results. Steroidal glycoalkaloids are naturally occurring nitrogen containing secondary metabolites found in plants of the Solanaceae family. Solamargine, a steroidal alkaloid glycoside extracted from the traditional Chinese herb Sola- FOXO3a and SP1  contributed  to  the induction of  IGFBP1 expression  by solamargine, and overexpression of IGFBP1 restored the effect of solamargine on cell growth inhibition. A, Cellular protein was isolated from A549 and PC9 cells transfected with control or FOXO3a siRNAs for up to 30 h before exposing the cells to SM (6 µM) for an additional 24 h. Afterwards, the expressions of FOXO3a and IGFBP1 proteins were detected by Western blot. B, A549 and PC9 cells were transfected with control or SP1 overexpression vectors for 24 h before exposing the cells to SM for an additional 24 h. Afterwards, SP1 and IGFBP1 protein expressions were determined by Western blot. C, Cellular protein was isolated from A549 and PC9 cells transfected with control or FOXO3a expression vectors for up to 30 h before exposing the cells to SM (6 µM) for an additional 24 h. Afterwards, the expressions of FOXO3a and IGFBP1 proteins were detected by Western blot. D, Cellular protein was isolated from A549 and PC9 cells transfected with control or IGFBP1 expression vectors for up to 30 h before exposing the cells to SM (6 µM) for an additional 24 h. Afterwards, the phosphorylation of Stat3 and expression of IGFBP1 protein were detected by Western blot. GAPDH was used as loading control. E, A549 and PC9 cells were transfected with control or IGFBP1 siRNAs for 24 h before exposing the cells to SM (6 µM) for an additional 24 h. Afterwards, the cells were collected and processed for MTT assay as described in the Materials and Methods section. *Indicates significant difference as compared to the untreated control group (P<0.05); **Indicates significance of combination treatment as compared to SM alone (P<0.05). Fig. 6 . In vivo anti-tumor efficacy of solamargine in mice. Mice (n=9/ group) were divided to 4 groups [Con (saline), metformin (Met, 250 mg/kg), solamargine (SM, 8 mg/ kg), and SM plus Met] and SM was given at the 8 th day after tumor cells via intraperitoneal injection for up to 27 days. A, the xenografts were assessed by in vivo bioluminescence imaging at the initial and end of the experiments (on day 8 and 27). The tumor growth was monitored by injecting luciferin in the mice followed by measuring bioluminescence using IVIS Imaging System. Imaging and quantification of signals were controlled by the acquisition and analysis software living image as described in the Materials and Methods section. Representative images are shown. B and C, The xenografts were harvested on day 27, and the volume and weight of tumors were measured. D, The photographs of vehicle-and drugs-treated xenografts derived from nude mice are shown. E-F, At the end of the experiments, xenografted tumors were isolated from individual animals and the corresponding lysates were processed and detected FOXO3a, SP1 and IGFBP1 by Western blot with the indicated antibodies and Immunohistochemistry as described in the Materials and Methods sections. Scale bar 50 mM. GAPDH was used as loading control for Western blot. The bar graphs represented the tumor weight and volume of mice results indicated as mean ± SD. *Indicates the significant difference from the untreated control (p<0.05). G, The diagram shows that solamargine inhibits growth of NSCLC cells through inactivation of Stat3, followed by reduction of SP1 and induction of FOXO3a; this ultimately induces the expression of IGFBP1 gene. There is synergy of combination of solamargine and metformin. Intriguingly, the interactions between FOXO3a and SP1 are required in regulating IGFBP1 gene expression in response to solamargine. Moreover, silencing of IGFBP1 abrogates solamargine-inhibited growth of NSCLC cells. [22, 50, 51] . Although there were important discoveries revealed by other studies indicated multiple signaling pathways and molecular genes or proteins that involved in the anti-tumor responses of solamargine, the in-depth molecular mechanisms by which this agent in inhibition of tumor growth still remained to be elucidated. Consistent with our previous report [21] , the current results further confirmed the anti-lung cancer effects of solamargine and suggested a potential therapeutic modality in lung cancer.
Cellular Physiology
Our findings indicated that inactivation of Stat3 was involved in the effect of solamargine on anti-lung cancer growth. As a cytoplasmic transcription factor that modulates the transcription of a variety of genes and regulates several biological functions including proliferation, differentiation, angiogenesis, progression and metastasis, constitutive activation of Stat3 was involved in oncogenic transformation and progression in several cancer types [52] [53] [54] . We observed that inactivation of Stat3 phosphorylation (Tyr705) was occurred in the anti-lung cancer effect of solamargines. However, whether or not solamargines could affect other phosphorylation sites of Stat3 still remained to be determined. The phosphoryation (Tyr705) of Stat3 was reported to interacted with phosphatidylinositol 3-kinase (PI3-K)-induced oncogenic transformation and growth in both non-cancer and cancer cell types [52] [53] [54] [55] . Nevertheless, we reasoned that more experiments are required to further elucidate the true role of Stat3 phosphorylation affected by solamargines. Our results also suggested that inactivation of Stat3 was required in mediating the regulation of two important downstream effectors SP1 and FOXO3, thereby increasing expression of IGFBP1 and cell growth inhibition in our study. In line with this, inactivation and inhibition of Stat3 have been shown in other studies involving the inhibition of cancer cell growth and survival [5, 56, 57] suggesting that targeting this could be potential in cancer treatment.
As a bona fide pleiotropic tumor suppressor, FOXO3 negatively regulates cancer cell proliferation and progression by regulating the expression of genes involved in apoptosis, cell cycle, oxidative stress response, and angiogenesis. Also, transcription factor SP1 is a well known tumor promoter and is involved in the variety of biological functions including cancer cell growth. We demonstrated that both FOXO3a and SP1 were downstream effecters of Stat3 and that inactivation of Stat3 was involved in the induction of FOXO3a and reduction of SP1 in the effect of solamargine in this process. Regulation of FOXO3a and SP1 linked to the Stat3 signaling and involved in a number of cellular functions, such as tumorigenesis, progression, growth, and metastasis, has been shown in other studies [44, 45, 58] . The induction of FOXO3a and inhibition of SP1, and interaction between FOXO3a and SP1 have also been reported to be associated with regulation of other genes, thereby controlling cancer cell survival in other studies, this demonstrates the critical roles of these transcription factors in these processes [59] [60] [61] . For example, high expression of SP1 was observed in the ovarian cancer cells and that the SP1 inhibitor was found to enhance the response of cisplatin on growth inhibition [59] . Also, cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGF-R), stimulated FOXO3a expression and promoted its nuclear translocation, leading to induction of apoptosis and inhibition of proliferation in colorectal cancer cells [60] . Thus, FOXO3a and SP1 could be used as potential targets in treatment modality of cancer.
We also demonstrated an important role of SP1 and FOXO3a in mediating the effect of solamargine on IGFBP1 expression. A number of direct and indirect links between FOXO, SP1 and IGFBP1 have already been uncovered. These results reveal a complex mechanism axis, which have been involved in the regulation of other gene expressions, biological functions and tumor growth [62] [63] [64] . As common ubiquitous transcription factor that binds to GC-rich motifs of several gene promoters, SP1 was involved in many cellular functions, such as growth, differentiation, and progression through regulation of several relevant genes [65] . Report found that SP1-like binding site in IGFBP1 promoter region was required for the regulation of IGFBP1 gene expression in human endometrial stromal cells [47] . Consistent with this, our findings suggested that reduction of SP1 may be required in the upregulation of IGFBP1 expression by solamargine. While Interestingly, we found that increased expression of IGFBP1 stimulated the solamargineinhibited lung cancer cell proliferation. In addition to inhibiting IGF receptors, IGFBP1 also suppress cancer cell proliferation, motility and progression via regulating several important downstream molecules or targets [27, 66, 67] , this highlights a tumor suppressor role. Consistent with these, our results suggested that induction of IGFBP1 was required in stimulating the solamargine-inhibited NSCLC growth. However, opposite results were also observed in other cancer types, such as prostate cancer [33, 34] and endometrial cancer [35] . Thus, the true functions of IGFBP1 acting as a tumor suppressor or oncogene may depend upon the capacity of environmental context, and agents exposed, which required to be determined. Our study suggested that IGFBP1 may be considered as a novel potential biomarker for lung cancer growth and progression, and that increased IGFBP1 could add compatible with current treatment regimes for lung cancer.
More importantly, our results suggested a possibility of the synergy of solamargine in combination with metformin. Metformin, an oral biguanide commonly used for treating type II diabetes, has been reported to possess anti-cancer properties in a variety of tumor types using alone and combination with other agents, the latter showed greater effects [68, 69] . However, there was less information available regarding the combination of solamargine and metformin in cancer treatment. We previously observed that metformin facilitated the effect of solamargine on castration-resistant prostate cancer cells [42] . We reason that further understanding the potential molecular mechanisms of this combination effect may unveil greater potency and offer a possible new strategy in inhibition of lung cancer growth with minimal adverse outcomes and maximal efficiency. Thus, more studies are required to explore the in-depth mechanism and clinical significance of the potential synergy of solamargine in combination with metformin.
As expected, our in vivo data were consistent with the findings from that in vitro, confirming the effect of solamargine on lung cancer growth inhibition and regulation of SP1, FOXO3a and IGFBP1 expression in the presence or absence of metformin. The doses of solamargine used were based on our previous reports [22, 42] and other study [70] . In spite of this, future experiments are required to further determine the critical role of IGFBP1 in this process using cells stable transfected with shRNA and exogenously expression vector containing coding region of IGFBP1 gene in animal models.
Collectively, our results show that solamargine inhibits growth of NSCLC cells through inactivation of Stat3, followed by reduction of SP1 and induction of FOXO3a; this ultimately induces the expression of IGFBP1 gene. There is synergy of solamargine in combination with metformin. Intriguingly, the interaction between FOXO3a and SP1 are required in regulating IGFBP1 gene expression in response to solamargine. Moreover, silencing of IGFBP1 abrogates solamargine-inhibited growth of NSCLC cells (Fig. 6F) . This study unveils an additional novel mechanism by which solamargine alone or/and in combination with metformin inhibit growth of human lung cancer cells and provides new insights into IGFBP1-mediated cellular responses toward human lung cancer therapeutics. The true impact of these molecules above in the clinical arena in lung cancer patients, especially the activation/expressions of these molecules link to clinical outcomes, such as acting as potential biomarkers and therapeutic targets, still required to be determined in the future with more in-depth experimental approaches.
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